TrialCritical care (London, England)2018

The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.

Gunnar Elke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.